napabucasin
Small moleculeexperimental
Clinical trial activity
26 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
17
Phase 3
7
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT01775423)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Pancreatic Ductal · Phase 3
- Colorectal Neoplasms · Phase 3
- Drug Interactions · Phase 1
- Esophageal Neoplasms · Phase 3
- Glioblastoma · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Hematologic Neoplasms · Phase 1
- Intestinal Neoplasms · Phase 1/Phase 2
- Mesothelioma, Malignant · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 3
- Pharmacokinetics · Phase 1
- Stomach Neoplasms · Phase 3
Mechanism of action
STAT3 inhibitor
- Unspecified targetOTHER
Unknown
Not fully elucidated. Proposed to inhibit STAT-3 and/or the E3 Ligase ZFP91 (Q96JP5) or function through the generation of ROS.
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O- Mol. weight
- 240.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL64130 ↗
Also known as
- 2-acetylfuranonaphthoquinone
- 2-acetylfuranonaphthoquinone
- 2-acetyl furanonaphthoquinone
- 2-acetyl furanonapthoquinone
- bbi608
- bbi608
- bbi-608
- bbi-608
- fnq cpd
- napabucasin
- napabucasin
- napabucasin
- napabucasin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04299880 | Phase 1 | Feb 24, 2020 | Boston Biomedical |
| NCT03721744 | Phase 3 | Oct 25, 2018 | 1Globe Biomedical Co., Ltd. |
| NCT03647839 | Phase 2 | Aug 31, 2018 | Australasian Gastro-Intestinal Trials Group, Olivia Newton-John Cancer Research Institute |
| NCT03525405 | Phase 1 | May 18, 2018 | Boston Biomedical |
| NCT03416816 | Phase 1 | May 15, 2018 | Boston Biomedical, Syneos Health |
| NCT03522649 | Phase 3 | Apr 12, 2018 | 1Globe Biomedical Co., Ltd. |
| NCT03411122 | Phase 1 | Jun 30, 2017 | Boston Biomedical |
| NCT02993731 | Phase 3 | Dec 1, 2016 | Boston Biomedical |
| NCT02826161 | Phase 3 | Nov 1, 2016 | Boston Biomedical |
| NCT02851004 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | National Cancer Center Hospital East, Sumitomo Dainippon |
| NCT02753127 | Phase 3 | Jun 1, 2016 | Boston Biomedical |
| NCT02641873 | Phase 1 | Dec 1, 2015 | Sumitomo Dainippon |
| NCT02467361 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2015 | Boston Biomedical |
| NCT02352558 | Phase 1 | May 1, 2015 | Boston Biomedical |
| NCT02432326 | Phase 1 | Apr 1, 2015 | Boston Biomedical |
| NCT02315534 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2015 | Boston Biomedical |
| NCT02358395 | Phase 1 | Feb 1, 2015 | Sumitomo Dainippon |
| NCT02347917 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2015 | Sumitomo Dainippon |
| NCT02279719 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | Boston Biomedical |
| NCT02178956 | Phase 3 | Aug 1, 2014 | Boston Biomedical |
Showing 20 of 26 trials
Page 1 / 2
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Biomedical | For profit | 19 | 18 | 3 | 2009 |
| Sumitomo Dainippon | For profit | 4 | 3 | 2 | 2015 |
| 1Globe Biomedical Co., Ltd. | For profit | 2 | 2 | 1 | 2018 |
| Australasian Gastro-Intestinal Trials Group | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2013 |
| National Cancer Center Hospital East | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Olivia Newton-John Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Syneos Health | For profit | 1 | 0 | 1 | 2018 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2013 |
9 organizations
Page 1 / 1